Narrow your search by using the search box and/or filters to the left.
The cores administrative team is thrilled to announce that the Biomarkers Core will re-launch as the Pediatric Metabolomics and Biomarkers Core. Under Dr. Joshua Chandler's leadership, the PMBC will offer multiple new services, including polytargeted metabolomics, isotope tracing, and high-resolution MS imaging. The new core and services are expected to begin operating in summer 2025.
We are pleased to announce that 44 members of the Emory University School of Medicine Department of Pediatrics were honored as part of the 2025 National Doctors' Day Recognition; 20 of these honorees are Center members of the Children’s + Emory Pediatric Research Alliance. These Emory faculty members were nominated by their peers and colleagues for their dedication to improving the health and well-being of our patients and community through the care they provide, the research they conduct and their efforts to teach and inspire learners.
We congratulate each of these doctors on this recognition, celebrate their accomplishments, and thank them for their continued stellar contributions to our community!
Link here for more information and the complete listing of all honorees.
Seven members of the Emory faculty have been named by the American Association for the Advancement of Science (AAAS) as 2024 Fellows. The AAAS selects fellows for their outstanding efforts in the advancement of science based on research, teaching, administration and technology, as well as communicating and interpreting science to the public. Emory’s new fellows join a distinguished list of previous fellows including Thomas Edison, W. E. B. DuBois, retired astronaut Ellen Ochoa and former Secretary of Energy Steven Chu.
Emory faculty selected as 2024 AAAS Fellows include Tené T. Lewis, Edmund K. Waller, Anant Madabhushi, Ilya Nemenman, Wilbur Lam, Li Xiong and David H. Lawson. They will receive the AAAS gold and blue rosette pin (representing science and engineering, respectively) to commemorate their election and be celebrated at a D.C. forum in June.
Aflac Cancer and Blood Disorders Center (Aflac)
Marcus Center for Cellular Therapy
Pediatric Technology Center (PTC)
Research and Epidemiology for Adolescent and Child Health (REACH) Center
A small but powerful invention could make life in the NICU easier for the tiniest patients.
Newborns must have their vitals checked frequently, and one of the most critical measures of newborn health is electrolyte levels. Right now, the only way to monitor electrolytes is to draw their blood multiple times a day. This can be painful and frightening for babies, and challenging to perform for medical staff, who can have trouble drawing blood from tiny, underdeveloped blood vessels.
Now, researchers at the Georgia Institute of Technology have developed a pacifier designed to monitor a baby’s electrolyte levels in real time, potentially eliminating the need for repeated invasive blood draws.
Hong Yeo, associate professor and Harris Saunders Jr. Endowed Professor in the George W. Woodruff School of Mechanical Engineering, came up with the pacifier idea at a pediatric technology conference. Doctors described daily challenges they face in caring for sick newborns, and the lack of noninvasive monitoring systems.
Click here to read the full story.
Pediatric Technology Center (PTC)
Emory + Children’s Announce Launch of the Research and Epidemiology for Adolescent and Child Health (REACH) Center
Emory and Children’s have launched the Research and Epidemiology for Adolescent and Child Health (REACH) Center. Led by newly recruited distinguished faculty members, Philip Lupo, PhD and Michael Scheurer, PhD, and in partnership with the former Center for Clinical Research and Public Health (CORPH) Interim Director, Shasha Bai, PhD, REACH is designed to serve as a leading hub for child-focused and population-based research and aims to advance collaborative research initiatives to improve pediatric health outcomes.
REACH builds upon the work of the Center for CORPH, which was founded in 2011 by Dr. Ann Mertens to support child health-focused clinical outcomes and public health research. CORPH has played a crucial role in promoting high-quality epidemiologic and clinical research, mentoring young investigators, and linking healthcare practices to patient outcomes to improve quality of care. The work of CORPH was transformative and has led to this important next phase.
Research and Epidemiology for Adolescent and Child Health (REACH) Center
Clinical Outcomes Research & Public Health (CORPH)
This 40-page report highlights the incredible accomplishments of Children's-Emory researchers in 2024 and shares our vision for research moving forward.
National Institutes for Health (NIH) funding is critical to ensure academic medical centers continue to pursue innovative research in areas that advance patient care and human health. As a leading R1 research institute, Emory University is forging new pathways to advance science and clinical care through this essential federal funding.
Each year, the Blue Ridge Institute for Medical Research (BRIMR) publishes a ranking of U.S. academic institutions and health care systems based on the research funding they received from NIH the prior year.
In 2024, Emory received more than $488 million and is among the top 20 in the nation overall for institutional funding from the NIH.
Heart disease is the number one cause of death in women, yet few young women know their heart disease risk or the steps they can take to improve their heart health. Our team, led by Dr. Holly Gooding, worked collaboratively with adolescents to create a heart health screening tool and successfully incorporated it into adolescent reproductive health and primary care visits.
Children's Heart Research and Outcomes Center (HeRO)
Clinical Outcomes Research & Public Health (CORPH)
Emory University is hopeful that a new study will lead to a breakthrough in childhood cancer treatment. The university says new research from a partnership with Australia's QIMR Berghofer Medical Research Institute shows a potential new targeted treatment for brain cancer in children.
In a recent paper published in the journal Nature Communications, the researchers say the novel drug CT-179 was shown to be effective in killing tumor cells in preclinical models using mice.
The drug specifically targeted tumor cells that are resistant to standard treatments, which could lead to more effective and less toxic treatments.
The researchers say the drug could possibly apply to other brain cancers as well.
Timothy Gershon, MD, PhD was one of the study's lead researchers. He is an Emory University Professor and also a pediatric neurologist at Children’s Healthcare of Atlanta and director of the Children’s Center for Neurosciences Research.
Children's Center for Neurosciences Research (CCNR)
With administration once a day, Alyftrek offers an additional treatment option for patients with cystic fibrosis and provides a simpler dosing regimen for people with cystic fibrosis, as compared to twice daily for other modulators.
Center for Cystic Fibrosis and Airways Disease Research (CF-AIR)
